Read + Share
Lam CSP, Gerstein HC. Response by Lam and Gerstein to Letter Regarding Article, "Efpeglenatide and
Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2
Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O
Trial". Circulation 2022;146:e7.
PMID: 35858159
|
 |
|
